Celldex Therapeutics
CLDX
115 hedge funds and large institutions have $710M invested in Celldex Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 33 closing their positions.
38% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $16.3M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more capital invested
Capital invested by funds: $645M → $710M (+$64.5M)
3% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 38
5.84% less ownership
Funds ownership: 93.04% → 87.2% (-5.8%)
12% less funds holding
Funds holding: 130 → 115 (-15)
45% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.2M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$15.5M |
| 3 |
RI
RTW Investments
New York
|
+$11.2M |
| 4 |
VA
VR Adviser
New York
|
+$10.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$28.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$17.7M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$17.5M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$14M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.8M |
CLDX Hedge Fund Activity: Q1 2021 in Review
115 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2021, worth a combined $710M — up 10% from $645M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of CLDX and 18 opened new positions — a net loss of 15 holders — while 38 trimmed existing stakes and 39 added.
The largest buyer was Wellington Management Group, adding an estimated $41.2M. The largest seller was Marshall Wace North America, cutting an estimated $28.9M.
- 115 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2021, down from 130 in Q4 2020.
- Funds reported $710M of Celldex Therapeutics stock for Q1 2021, up 10% quarter-over-quarter.
- 18 funds opened new Celldex Therapeutics positions in Q1 2021 and 33 closed out, a net change of -15 holders.
- The largest Celldex Therapeutics buyer in Q1 2021 was Wellington Management Group, an estimated $41.2M added.
- The largest Celldex Therapeutics seller in Q1 2021 was Marshall Wace North America, an estimated $28.9M sold.
Based on aggregated 13F filings for Q1 2021.